GSK team launches CRO Biodextris
Friday, April 1, 2016
Biodextris, a Canada-based CRO, has launched. The new CRO provides analytical and process development services for vaccines and biologics products.
Formerly part of the GSK-Vaccines principal North American R&D unit, the Biodextris team is comprised of key senior development scientists. Together, they have developed dozens of products for early phase clinical trials conducted in the U.S., Canada and Europe.
When GSK ceased operations at the Laval facility in 2015, the team capitalized on the opportunity to offer their collective industry expertise as an independent service provider. Multinationals as well as small and medium enterprises use Biodextris’ analytical and process development services to advance their candidate vaccine and biologic products from the bench to the clinic.
“Our history within successful commercial organizations makes us an ideal partner to efficiently move products from candidate selection through clinical development,” said Joseph Zimmermann, CEO of Biodextris. “The team’s passion, coupled with our capabilities and formal quality management systems, enable our vision to become a full service process development and manufacturing organization.”
An advantageous location in Canada’s premier life sciences hub, allows Biodextris to provide cost competitive services to companies in the clinical phases of product development for complex vaccine and biologics products.
“Our quality management system is the backbone of everything we do,” said Christine Jacques, analytical services director. “It is the reason large multinational pharmaceutical and innovative vaccine and biologics companies work with us.”